TGFB1 and cancer: In conclusion, our study demonstrates the therapeutic potential of combining CAR T cells, oncolytic virus OVV-mIL21 and TGF-β inhibition in an immunocompetent model of PDAC, which is one of the most challenging cancers to treat.